22 December 2020 - Data show Darzalex in combination with bortezomib, thalidomide and dexamethasone before and after autologous stem cell transplant improved response rates and progression-free survival compared to bortezomib, thalidomide and dexamethasone alone.
Janssen announce that Health Canada has approved Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone (VTd) for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation.
The approval is based on results from the Phase 3 CASSIOPEIA (MMY3006) study that demonstrated the addition of Darzalex to VTd before and after ASCT resulted in deeper responses, as indicated by the higher stringent complete response rate, and improved progression-free survival compared to VTd alone.